NO147243C - Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater

Info

Publication number
NO147243C
NO147243C NO770109A NO770109A NO147243C NO 147243 C NO147243 C NO 147243C NO 770109 A NO770109 A NO 770109A NO 770109 A NO770109 A NO 770109A NO 147243 C NO147243 C NO 147243C
Authority
NO
Norway
Prior art keywords
phtaland
derivatives
preparation
therapeutic active
analogy procedure
Prior art date
Application number
NO770109A
Other languages
English (en)
Other versions
NO147243B (no
NO770109L (no
Inventor
Klaus Peter Boegesoe
Anders Stausboell Toft
Original Assignee
Kefalas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO147243(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas As filed Critical Kefalas As
Publication of NO770109L publication Critical patent/NO770109L/no
Publication of NO147243B publication Critical patent/NO147243B/no
Publication of NO147243C publication Critical patent/NO147243C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
NO770109A 1976-01-14 1977-01-13 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater NO147243C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (3)

Publication Number Publication Date
NO770109L NO770109L (no) 1977-07-15
NO147243B NO147243B (no) 1982-11-22
NO147243C true NO147243C (no) 1983-03-02

Family

ID=9722860

Family Applications (2)

Application Number Title Priority Date Filing Date
NO770109A NO147243C (no) 1976-01-14 1977-01-13 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater
NO1996001C NO1996001I1 (no) 1976-01-14 1996-01-05 Citalopram

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1996001C NO1996001I1 (no) 1976-01-14 1996-01-05 Citalopram

Country Status (19)

Country Link
US (1) US4136193A (no)
JP (1) JPS52105162A (no)
AT (1) AT359488B (no)
AU (1) AU509445B2 (no)
BE (1) BE850401A (no)
CA (1) CA1094087A (no)
CH (3) CH626886A5 (no)
DE (1) DE2657013C2 (no)
DK (1) DK143275C (no)
ES (1) ES454980A1 (no)
FI (1) FI63754C (no)
FR (1) FR2338271A1 (no)
GB (1) GB1526331A (no)
IE (1) IE44055B1 (no)
NL (2) NL192451C (no)
NO (2) NO147243C (no)
NZ (1) NZ183001A (no)
SE (1) SE429551B (no)
ZA (1) ZA7757B (no)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ATE192042T1 (de) * 1995-08-16 2000-05-15 Lilly Co Eli Potenzierung von serotonin-wirkstoffresponz
PT1015416E (pt) * 1997-07-08 2002-03-28 Lundbeck & Co As H Metodo para a producao de citalopram
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
BR9714925A (pt) * 1997-11-11 2003-07-22 Lundbeck & Co As H Método para preparação de citalopran, composto e composição farmacêutica antidepressiva
KR100411505B1 (ko) 1998-10-20 2003-12-18 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조방법
KR20010081071A (ko) 1998-12-08 2001-08-25 피터슨 존 메이달 벤조푸란 유도체, 그것들의 제조 및 사용
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
SI1140886T1 (en) 1998-12-23 2003-08-31 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
CA2291129C (en) * 1999-04-14 2002-10-22 H. Lundbeck A/S Method for the preparation of citalopram
ITMI991579A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
ES2229774T3 (es) * 1999-10-25 2005-04-16 H. Lundbeck A/S Metodo para la preparacion de citalopram.
EA002801B1 (ru) 1999-10-25 2002-10-31 Х.Лундбекк А/С Способ получения циталопрама
US6310222B1 (en) 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
KR20020073489A (ko) 1999-12-28 2002-09-26 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
CN1211377C (zh) * 1999-12-30 2005-07-20 H.隆德贝克有限公司 西酞普兰的制备方法
IL150561A0 (en) * 2000-01-14 2003-02-12 Lundbeck & Co As H Method for the preparation of 5-cyanophthalide
US6433196B1 (en) * 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
FR2805812A1 (fr) 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
JP2003527387A (ja) * 2000-03-13 2003-09-16 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
NL1017500C1 (nl) 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
EP1265881A1 (en) * 2000-03-13 2002-12-18 H. Lundbeck A/S Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AU2001239213A1 (en) 2000-03-14 2001-09-24 H Lundbeck A/S Method for the preparation of citalopram
MXPA02008652A (es) * 2000-03-16 2003-02-24 Lundbeck & Co As H Metodo para la preparacion de 5-ciano-1-(4-fluorofenil)-1,3-dihidroisobenzofuranos.
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
WO2002004435A1 (en) * 2000-07-06 2002-01-17 H. Lundbeck A/S Method for the preparation of citalopram
ES2238466T3 (es) * 2000-07-21 2005-09-01 H. Lundbeck A/S Compuestos y su uso como inhibidores del transporte de glicina.
IES20010693A2 (en) * 2000-08-10 2002-07-10 Lundbeck & Co As H Pharmaceutical composition containing citalopram
IL144817A0 (en) * 2000-08-18 2002-06-30 Lundbeck & Co As H Method for the preparation of citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
TR200201166T1 (tr) * 2000-12-22 2002-10-21 H.Lundbecks A/S Saf sitalopram hazırlanması için yöntem
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
AU3920201A (en) * 2000-12-28 2001-07-09 H. Lundbeck A/S Process for the preparation of pure citalopram
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
WO2002060886A1 (en) * 2001-01-30 2002-08-08 Orion Corporation, Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
US20040133017A1 (en) * 2001-02-22 2004-07-08 Pulla Reddy Muddasani Process for the preparation of citalopram
GB0105627D0 (en) 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
WO2002072565A1 (en) * 2001-03-09 2002-09-19 Ranbaxy Laboratories Limited Process for the preparation of citalopram
MEP5908A (xx) * 2001-05-01 2010-02-10 Lundbeck & Co As H Upotreba enantiomerno čistog escitaloprama
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (no) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
DK1522539T3 (da) * 2001-07-31 2007-05-07 Lundbeck & Co As H Krystallinsk komposition indeholdende excitalopram
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
US7119083B2 (en) * 2001-10-12 2006-10-10 Azevan Pharmaceuticals, Inc. β-Lactamyl vasopressin V1a Antagonists
IN192863B (no) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
US7148364B2 (en) * 2002-01-07 2006-12-12 Sun Pharmaceutical Industries Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
GB2387596B (en) * 2002-02-27 2004-02-11 Matrix Lab Ltd Process
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
US7196224B2 (en) * 2002-03-27 2007-03-27 Bando Chemical Industries, Ltd. 1,3,5-tris(arylamino)benzenes
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
TWI306846B (en) 2002-08-12 2009-03-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
WO2004016602A1 (en) * 2002-08-14 2004-02-26 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
MXPA05005772A (es) * 2002-12-23 2005-08-16 Lundbeck & Co As H Bromhidrato de escitalopram y un metodo para su preparacion.
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
WO2004065375A1 (en) * 2003-01-17 2004-08-05 Natco Pharma Limited Processes for the preparation of escitalopram and its precursor
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
EP1486492A3 (en) * 2003-06-10 2005-02-23 Sun Pharmaceuticals Industries Ltd. A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran.
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
BRPI0414541B8 (pt) * 2003-09-17 2021-05-25 Janssen Pharmaceutica Nv compostos heterocíclicos fundidos tendo atividade de modulação de receptor de serotonina, método de preparação de compostos intermediários
CA2546422A1 (en) * 2003-10-28 2005-05-12 Wockhardt Limited Improved process for the manufacture of citalopram hydrobromide
SI1506963T1 (en) * 2003-10-28 2005-10-31 Adorkem Technology Spa Method for the preparation of citalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
AU2004305563C1 (en) 2003-12-11 2011-07-07 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
CA2559703A1 (en) * 2004-02-16 2005-08-25 Jubilant Organosys Limited One pot synthesis of citalopram from 5-cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006021971A2 (en) * 2004-08-23 2006-03-02 Sun Pharmaceutical Industries Limited 'process for preparation of citalopram and enantiomers'
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
JP2008538573A (ja) * 2005-04-22 2008-10-30 ワイス ベンゾフラニルアルカナミン誘導体およびその５−ｈｔ２ｃアゴニストとしての使用
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
EP1871356A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
NZ565683A (en) * 2005-07-08 2011-04-29 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis in human neural cells
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
DK1910346T3 (da) * 2005-07-19 2019-05-27 Azevan Pharmaceuticals Inc Beta-lactamyl fenylalanin, cystein og serin vasopressin antagonist
EP1909777A2 (en) * 2005-07-22 2008-04-16 Myriad Genetics, Inc. High drug load formulations and dosage forms
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
WO2007054105A2 (en) * 2005-11-14 2007-05-18 H. Lundbeck A/S Method for the preparation of escitalopram
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AR060087A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento de la depresion
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
DK1988086T4 (en) 2007-04-23 2015-03-02 Synthon Bv Method of dissolving citalopram via its (S) -riched citalopram tartrate compound
CA2685424A1 (en) * 2007-05-18 2008-11-27 Cipla Limited Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the s-isomer
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
DK3093291T3 (da) 2009-10-23 2019-07-29 Janssen Pharmaceutica Nv Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer
WO2012003436A1 (en) 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
MX2016012645A (es) 2014-03-28 2017-01-11 Azevan Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades neurodegenerativas.
HUE058759T2 (hu) 2016-03-10 2022-09-28 Janssen Pharmaceutica Nv Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával
BR112020005107A2 (pt) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. composições e métodos para o tratamento de lesão cerebral

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (no) * 1965-03-18

Also Published As

Publication number Publication date
AT359488B (de) 1980-11-10
FI770073A (no) 1977-07-15
AU509445B2 (en) 1980-05-15
AU2107377A (en) 1978-07-13
NL192451C (nl) 1997-08-04
ATA947276A (de) 1980-04-15
CA1094087A (en) 1981-01-20
FR2338271B1 (no) 1982-11-05
US4136193A (en) 1979-01-23
SE7614201L (sv) 1977-07-15
NL192451B (nl) 1997-04-01
GB1526331A (en) 1978-09-27
CH632258A5 (de) 1982-09-30
DK143275C (da) 1982-01-18
IE44055B1 (en) 1981-07-29
IE44055L (en) 1977-07-14
ZA7757B (en) 1977-11-30
NZ183001A (en) 1978-06-02
NL970031I1 (nl) 1997-10-01
DK13177A (da) 1977-07-15
NL7700244A (nl) 1977-07-18
CH632259A5 (de) 1982-09-30
CH626886A5 (no) 1981-12-15
NO1996001I1 (no) 1996-01-05
NO147243B (no) 1982-11-22
NL970031I2 (nl) 1997-10-01
FR2338271A1 (fr) 1977-08-12
DK143275B (da) 1981-08-03
BE850401A (fr) 1977-07-14
JPS6135986B2 (no) 1986-08-15
ES454980A1 (es) 1978-04-01
JPS52105162A (en) 1977-09-03
FI63754B (fi) 1983-04-29
FI63754C (fi) 1983-08-10
DE2657013A1 (de) 1977-07-28
NO770109L (no) 1977-07-15
DE2657013C2 (de) 1985-11-14
SE429551B (sv) 1983-09-12

Similar Documents

Publication Publication Date Title
NO147243C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalanderivater
NO151321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater
NO151463C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolinderivater
NO151411C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-aryloksy-2-hydroksy-3-alkylenaminopropan-derivater
NO149586C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive polypeptider
NO148453C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spirohydantoinderivater
NO800881L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater
NO144848C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme 4-hydroksyfenylalkanolamin-derivater
NO148777C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antrakinon-derivater
NO149065C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater
NO150044C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrazol-derivater
NO145842C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive indolizinderivater
NO149313C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO145951C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolinderivater
NO149037C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO148291C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive basisk substituerte teofyllinderivater
NO148454C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidin-dionderivater
NO148488C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive acyl-benzimidazol-2-derivater
NO145163C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive antitumorglykosider
NO143903C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-fluorpyrimidin-4-on-derivater
NO794318L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive spiro-kinolyl-hydantoin-derivater
NO146710C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylpiperazinderivater
NO152556C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive antracen-biskarbonylhydrazoner
NO146600C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolderivater
NO147273C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive cykloheksadien-derivater